Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Urology Reports
Erschienen in: Current Urology Reports 6/2012

01.12.2012 | Benign Prostatic Hyperplasia (K McVary, Section Editor)

Acetylcholine for Male LUTS

verfasst von: Steven J. Weissbart, Bilal Chughtai, Dean Elterman, Richard Lee, Alexis Te, Steven Kaplan

Erschienen in: Current Urology Reports | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

In this review, we present the evidence on the safety and efficacy of anticholinergic therapy for men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and emphasize the data published over the past year. This review discusses two classes of medications whose mechanism of action attenuates the effect of acetylcholine on the LUT: anticholinergics and botulinum toxin. We review the randomized controlled trials that investigate the efficacy and side effects of anticholinergics when used in men with LUTS secondary to BPH. We emphasize new studies and developments that have been made in the past year.
Literatur
1.
McVary KT. BPH: Epidemiology and comorbidities. Am J Manag Care. 2006;12(5):122.
2.
3.
Taylor BC, Wilt TJ, Fink HA, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: The MrOS study. Urology. 2006;68(4):804–9.PubMedCrossRef
4.
Foley CL, Taylor C, Kirby RS. Counting the cost of treating benign prostatic hyperplasia. BJU Int. 2004;93:250–2.PubMedCrossRef
5.
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol. 2006;50(6):1306–15.PubMedCrossRef
6.
Van Venrooij G, Boon T, De Gier R. International prostate symptom score and quality of life assessment versus urodynamic parameters in men with benign prostatic hyperplasia symptoms. J Urol. 1995;153(5):1516–9.PubMedCrossRef
7.
Charlton R, Morley A, Chambers P, Gillespie J. Focal changes in nerve, muscle and connective tissue in normal and unstable human bladder. BJU Int Br J Urol Incl Free CD ROM. 1999;84(9):953–60.
8.
Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434–41.PubMedCrossRef
9.
van Venrooij GEPM, van Melick HHE, Eckhardt MD, Boon TA. Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol. 2002;168(2):605–9.PubMedCrossRef
10.
Dahm T, Ostri P, Kristensen J, et al. Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: A double-blind placebo-controlled multicenter investigation. Urol Int. 1995;55(4):205–8.PubMedCrossRef
11.
Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175(3):999–1004.PubMedCrossRef
12.
Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: A prospective, randomized, controlled multicenter study. J Urol. 2005;174(4):1334–8.PubMedCrossRef
13.
Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an [alpha]-blocker plus an anticholinergic for bladder outlet obstruction: A prospective, randomized, controlled study. J Urol. 2003;169(6):2253–6.PubMedCrossRef
14.
Blake-James BT, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta–analysis. BJU Int. 2007;99(1):85–96.PubMedCrossRef
15.
• Nishizawa O, Yamaguchi O, Takeda M, Yokoyama O. Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an Alpha–blocker combined with anticholinergics. LUTS. 2011;3(1):29–35. This study demonstrated the efficacy of combination therapy (tamsulosin + propiverine) for BPH with overactive bladder.
16.
• Bae JH, Kim SO, Yoo ES, Moon KH, Kyung YS, Kim HJ. Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: A prospective, randomized, single-blinded and multicenter clinical trial. Korean J Urol. 2011;52(4):274. This study demonstrated efficacy of combination therapy (Alfuzosin + propiverine) for BPH/LUTS.PubMedCrossRef
17.
• Lee S, Chung B, Kim S, Kim J, Kim J, Lee J. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: A prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer Prostatic Dis. 2011. This study demonstrated efficacy of combination therapy (doxazosin + tolterodine) for BPH/LUTS.
18.
Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA. 2006;296(19):2319–28.PubMedCrossRef
19.
• Yokoyama T, Uematsu K, Watanabe T, Sasaki K, Kumon H, Nagai A. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: A prospective randomized controlled study. Scand J Urol Nephrol. 2009;43(4):307–14. This was a study demonstrating efficacy of combination therapy (naftopidil + propiverine) for BPH/LUTS compared to propiverine monotherapy.PubMedCrossRef
20.
• Oelke M, Murgas S, Baumann I, Schnabel F, Michel MC. Efficacy of propiverine ER with or without alpha-blockers related to maximum urinary flow rate in adult men with OAB: Results of a 12-week, multicenter, non-interventional study. World J Urol. 2011;29(2):217–23. This was a study examining anticholinergic monotherapy (propiverine) compared to combination therapy with an α-blocker.PubMedCrossRef
21.
• Chung DE, Te AE, Staskin DR, Kaplan SA. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology. 2010;75(5):1144–8. This is the only study addressing combination therapy including a 5ARI.PubMedCrossRef
22.
Kaplan SA, Zoltan E, Te AE. Safety and efficacy of tolterodine, solifenacin, and darifenacin in men with lower urinary tract symptoms (LUTS) on alpha-blockers with persistent overactive bladder symptoms (OAB). J Urol. 2008;179:701. Abstract 2036.CrossRef
23.
•• McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803. These are the AUA guidelines on the management of BPH with recommendations pertaining to anticholinergic use.PubMedCrossRef
24.
•• European Association of Urology: Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO)BPH Guidelines. Available at http://​www.​uroweb.​org/​guidelines/​online-guidelines/​. Accessed May 2012. These are the EAU guidelines on the management of BPH with recommendations pertaining to anticholinergic use.
25.
Smith CP, Franks ME, McNEIL BK, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol. 2003;169(5):1896–900.PubMedCrossRef
26.
•• Chancellor MB, Somogyi GT, Smith CP. Mechanism of Action of Botulinum Neurotoxin in the Lower Urinary Tract. In: Jankovic JP, editor. Botulinum Toxin-Therapeutic Clinical Practice and Science. Pennsylvania: Elsevier Inc; 2009. p. 231–40. This is an excellent review on botulinum toxin regarding the lower urinary tract.
27.
• Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Libr. 2011. This was a Cochrane study regarding the efficacy of botulinum toxin injection for OAB.
28.
Lee DJ, Sheth S, Chughtai B, et al. Randomized Double-blind Placebo Controlled Trial of Intradetrusor Injections of Botulinum Toxin for the Treatment of Refractory Overactive Bladder Secondary to Benign Prostatic Hyperplasia [abstract 1971]. Presented at the AUA Annual Meeting, Atlanta Georgia; May 22, 2012.
29.
Oeconomou A, Madersbacher H. Botulinum neurotoxin A for benign prostatic hyperplasia. Curr Opin Urol. 2010;20(1):28.PubMedCrossRef
30.
Maria G, Brisinda G, Civello I, et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003;62:259–64.PubMedCrossRef
31.
Chuang YC, Chancellor MB. The application of botulinum toxin in the prostate. J Urol. 2006;176(6 Pt 1):2375–82.PubMedCrossRef
32.
Thomas CA, Chuang YC, Giannantoni A, Chancellor MB. Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms. Curr Urol Rep. 2006;7(4):266–71.PubMedCrossRef
33.
Chartier-Kastler E, Mehnert U, Denys P, Giuliano F. Botulinum neurotoxin A for male lower urinary tract symptoms. Curr Opin Urol. 2011;21(1):13–21.PubMedCrossRef
34.
•• Crawford ED, Hirst K, Kusek JW, et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: A phase II randomized clinical trial. J Urol. 2011;186(3):965–70. This was a phase II trial regarding the use of intraprostatic botulinum toxin for BPH/LUTS.PubMedCrossRef
Metadaten
Titel
Acetylcholine for Male LUTS
verfasst von
Steven J. Weissbart
Bilal Chughtai
Dean Elterman
Richard Lee
Alexis Te
Steven Kaplan
Publikationsdatum
01.12.2012
Verlag
Current Science Inc.
Erschienen in
Current Urology Reports / Ausgabe 6/2012
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-012-0276-7

Weitere Artikel der Ausgabe 6/2012

Current Urology Reports 6/2012 Zur Ausgabe

Office Urology (N Shore, Section Editor)

A Reappraisal of Storage and Voiding Dysfunction

Benign Prostatic Hyperplasia (K McVary, Section Editor)

The Impact of Prostate Biopsy on Urinary Symptoms, Erectile Function, and Anxiety

Benign Prostatic Hyperplasia (K McVary, Section Editor)

In 2013, Holmium Laser Enucleation of the Prostate (HoLEP) May Be the New ‘Gold Standard’

Benign Prostatic Hyperplasia (K McVary, Section Editor)

Testosterone Replacement Therapy and Prostate Health

Office Urology (N Shore, Section Editor)

Update on Vasectomy Protocol

Office Urology (N Shore, Section Editor)

Office Ultrasound for the Urologist

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise